| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21be862ef0c5366bb75fcdbe7cb20406 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2430-36 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L24-046 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-765
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L31-16 |
| filingDate |
2008-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c601becd43f7323969c2f72ea88cfa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_633aa087f9fdd4a30daab9dbfbf65c16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b9e01fc6f3a185585571349cb85337d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98438de2cb6954a6c4faf67787cffc2a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f29da932b40d321a8fe8d6ebb9f19037 |
| publicationDate |
2009-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2706742-A1 |
| titleOfInvention |
Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent |
| abstract |
The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or AV-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets. This process results in the rapid formation of a platelet-mediated thrombus about the solid-phase agent causing vessel occlusion. |
| priorityDate |
2007-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |